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The cause and timing of first liver allograft failure 
was evaluated in 177 patients who underwent a second 
liver transplant between January 1984 and December 
1988. The population studied consisted of 94 men 
and 83 women with a mean age 41.3 ± 1.0 yr 
(mean ± S.E.M.). Mean first-graft survival was 
130.6 ± 22.9 days (range = 0 to 2.073 days). Sixty·eight 
percent of the grafts failed in the first postoperative 
month. 26% failed between the second and twelfth 
month and only 6% failed beyond the twelfth month 
from the date of the initial transplant. Six principal 
causes of graft failure were identified. Early allograft 
losses occurred as a result of four major problems: 
primary graft nonfunction (30.0% of all grafts; mean 
graft survival = 3.4 ± 0.3 days); ischemic injury of the 
graft without overt vascular injury (9.6%; mean graft 
survival = 17.5 ± 1.9 days); acute rejection (10.7%; 
mean graft survival = 30.4 ± 6.4 days); and overt vas-
cular complications (26.6%; mean graft sur-
vival = 59.6 ± 24.1 days). Late graft failures were the 
result of either chronic rejection (11.3%: mean graft 
survival = 496.3 ± 138.0 days) or recurrence of the 
primary liver disease (6.8%: mean graft sur-
vival = 550.5 ± 172.1 days). Graft failure occurred 
as a result of a variety of miscellaneous causes in 
5% of the cases (mean graft survival in this 
group = 300.0 ± 110.6 days). Overall 6-mo patient sur-
vival after a second liver transplant was 46.3%. Pa-
tients who had a retransplant because of chronic 
rejection and ischemic injury had the greatest (65%) 
and least (23%) 6-mo survival rates respectively after 
second grafting (p < 0.05). Those who survived the 
second transplant procedure for 6 mo or more tended 
to be younger (p < 0.01) and had a reduced first 
transplant requirement for red blood cells (p < 0.05), 
platelets (p < 0.01) and fresh frozen plasma (p < 0.01) 
than did those who died during the 6 mo after their 
second transplant procedure. (HEPATOLOGY 1991;14: 
1054-1062.) 
Orthotopic liver transplantation (OLTx) has pro-
foundly altered the otherwise fatal outcome for patients 
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with end-stage liver disease. One-year survival rates 
after OLTx exceed 70% at most centers 0-3). Despite 
improvements in organ procurement, surgical tech-
nique, postoperative care and immuosuppression, 
primary failure of a hepatic allograft remains an im-
portant clinical problem (1-3), and primary graft failure 
often determines the success or failure of a given 
transplant procedure. This unpredictable complication 
leads to early retransplantation in 10% to 20% of the 
patients undergoing OLTx (1-8). Available data from 
several institutions indicate that graft rejection, tech-
nical problems and ischemic injury of the allograft 
account for most of these early graft failures (1, 3, 5-7). 
In addition, cases of primary disease recurrence have 
been reported as a cause of late graft failure 0, 3). A 
complete picture of the causes and timing of initial 
allograft liver failure and the factors that contribute to 
such graft failures remain to be established. Knowledge 
of such issues should lead to a reduction in the frequency 
of this particular problem and thereby improve the 
overall prognosis of patients undergoing OLTx. This 
study was undertaken to determine the causes and the 
timing of first liver graft failure and retransplantation 
and to determine the influence of primary graft failure 
and retransplantation on recipient survival. In addition, 
the relationships between the cause of initial graft 
failure and the primary liver disease; age and gender of 
the recipient; and the operative requirement for blood 
and blood products at the time of initial OLTx were 
assessed to determine whether predictions might be 
possible as to which recipients are at greater or lesser 
risk of graft failure. 
PATIENTS AND METHODS 
The records of 180 adult patients receiving a second OLTx 
at the University of Pittsburgh between January 1984 and 
December 1988 were studied. Three of these patients had 
received their first OLTx at another institution and therefore 
were excluded from the study. Thus a final total of 177 patients 
having a failed primary liver graft were studied in detail. The 
initial OL Tx procedure was performed in 1982 in 3 patients, in 
1983 in 3 patients, in 1984 in 16 patients. in 1985 in 31 
patients. in 1986 in 42 patients, in 1987 in 38 patients and in 
1988 in 44 patients. Over this same time interval, a total of905 
transplant procedures were performed at this institution. The 
specific details for patient selection, the surgical procedure. the 
postoperative supportive care, the immunosuppressive reg-
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TABLE 1. Characterilltics of patients studied 
Primary liver Mean..., GeDder 
diNue" Number (yr" (M/F)" 
1.ChLD 54 43.4 ± 1.7 18/36 
2. Chronic PLD 85 40.5 ± 1.3 53/32 
3. NLD 16 50.9 ± 2.7d 13/3 
4. FHF 14 29.3 ± 3.9- 7/7 
5 MISC 8 37.7 ± 4.4 3/5 
TOTAL 177 41.3 ± 1.0 94/83 
OSee text for specific diseases included in each category. 
bMean ± S.E.M. 
'x2 for the distribution = 17.32 (p < 0.01). 
d p < 0.01 va. I, 2, 4 and 5. 
'p < 0.01 VB. 1 and 2. 
imens used and the follow-up clinical management of these 
patients have all been described previously (9-11). 
The sample experiencing primary graft failure consisted of 
94 men and 83 women ranging in age from 17 to 70 yr 
(41.3 ± 1.0, mean ± S.E.MJ The primary liver disease, 
gender distribution and mean age at the time of the first OLTx 
for these 177 patients are shown in Table 1. For statistical 
purposes, the primary liver diseases were distributed into five 
different categories. Category 1 was chronic cholestatic liver 
disease (ChLD), which included patients with PBC (n = 33), 
primary sclerosing cholangitis (n = 19), Caroli's disease 
(n = 1) and cystic fibrosis (n = 1). Category 2 was chronic 
parenchymal liver disease (PLD), which included patients with 
HBV-induced cirrhosis (n = 18), non A, non B (NANB) 
virus-induced cirrhosis (n = 21), autoimmune chronic liver 
disease (n = 9), ethanol-associated cirrhosis (n = 12), crypto-
genic cirrhosis (n = 15), ai-antitrypsin deficiency (n = 4), 
hemochromatosis (n = 3), Wilson's disease (n = 1), thorotrast 
cirrhosis (n = 1) and halothane cirrhosis (n = 1). Category 3 
was fulminant hepatic failure (FHF) occurring as a result of 
NANB virus infection in five patients, HBV infection in five 
patients (one of whom also had a delta virus infection) and 
uncertain cause in four patients. Category 4 was neoplastic 
liver disease (NLD), which included hepatocarcinoma (n = 8), 
fibrolamellar carcinoma (n = 3), epithelioid hemangioendo-
thelioma (n = 2), cholangiolar carcinoma (n = 2) and liver 
metastases from an intestinal carcinoid tumor (n = 1). Cat-
egory 5 was a miscellaneous group (MISC) consisting of 
patients with the Budd-Chiari syndrome (n = 3), polycystic 
liver disease (n = 2) and one each of nodular regenerative 
hyperplasia, congenital hepatic fibrosis and multiple hepatic 
adenomatosis. 
The intraoperative events occurring at the time of the first 
OLTx, the pretransplant and posttransplant clinical data 
including all diagnostic procedures performed between the 
first and second OL Tx, the operative findings at the time of 
the second OL Tx and the pathological findings in the failed 
liver graft were reviewed for each case. 
Although more than one factor often contributed to the 
failure of a given graft, only one factor was chosen for each 
patient as the principal factor responsible for the graft failure, 
with all of the remaining factors considered as contributory 
findings. This assignment was based. on a consensus consisting 
of at least four of the authors. The causes of graft liver failure 
were classified in one of the following seven categories: 
Category 1 was primary-graft nonfunction (PNF). This 
diagnosis was ascribed' to grafts that failed to demonstrate 
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FIG. 1. Timing of graft failure in the 177 patients studied. 
function immediately after OLTx and that had pathological 
evidence of ischemic necrosis and for which no specific 
technical cause could be identified; Category 2, ischemic graft 
injury without overt vascular injury OJ), was ascribed to grafts 
that initially functioned but eventually failed and that dem-
onstrated pathological findings of ischemic liver injury in the 
absence of any identifiable thrombotic or nonthrombotic 
structural abnormality of the hepatic artery (HA), the portal 
vein, the hepatic veins or the vena cava. Category 3, a diagnosis 
of acute rejection (AR), required the presence of histopatho-
logical evidence of severe acute rejection in the failed graft 
using previously well-described histopathological criteria (12). 
Category 4 was a diagnosis of a vascular complication (VC) that 
required both the demonstration of an HA, PV or hepatic 
venous thrombosis or vascular anastomotic abnormality, such 
as a vascular dissection or stricture that may have reduced the 
blood flow to the liver, and gross and microscopic hepatic 
pathological conditions characteristic of a vascular injury such 
as parenchymal necrosis, infarction, abscesses, bile duct 
necrosis or any combination of these problems (13). Category 
5 was chronic rejection (CR), which was diagnosed only in cases 
where the graft had well established histopathological evidence 
for severe CR (12). Category 6 was recurrence of the primary 
liver disease (REC), which was considered to have occurred in 
grafts that developed identical histopathological lesions as 
those present in the native liver and for which no other cause 
for this histopathological appearance could be identified (e.g., 
patients with HBV-induced primary liver disease, a positive 
serological result at the time of the diagnosis of recurrence and 
the demonstration of both HBsAg and HBcAg in the allograft 
liver). Category 7 included cases who did not fit into any of the 
above six groups; they were culled together as a miscellaneous 
(MISC) group. 
Graft survival was determined as the time interval between 
the first and second OL Tx in days. To evaluate the distribution 
of individual causes of graft failure across time, six arbitrary 
time periods were considered. Period 1 was 0 to 14 postoper-
ative days; period 2 was 15 to 30 postoperative days; period 3 
was 2 to 6 mo after OLTx; period 4 was 7 to 12 mo after OLTx; 
period 5 was 13 to 24 mo after OL Tx; and period 6 was more 
than 24 mo after OLTx. Patient survival was updated as of 
June 1989, with a minimum follow-up of 6 rno after the second 
OLTx. 
The preoperative diagnosis for the first graft failure was 
defined as the diagnosis found in the preoperative surgical 
record and was specified immediately before the second 
transplant procedure. Those matching with the diagnosis 
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TABLE 2. CaUllell of graft failure in cB.IeII8tudied 
Cauae of Number of Percent of 1'im.iq of graft 
graft failure patient. patient. fllilare (daY8)- A.8ociated fiDdinp in the graft 
1. PNF 53 
2. IJ 17 
3. AR 19 
4. VC 47 
5. CR 20 
6. REC 12 
7. MISC' 9 
30.0 
9.6 
10.7 
26.6 
11.3 
6.8 
5.0 
17.5 ± 1.9 
30.4 ± 6.4 
59.6 ± 24.1 
496.3 ± 136.()d 
550.5 ± 172.1d 
300.0 ± 110.6 
Moderate AR(2), Cholangitis (l), Herpes (1), Partial IH-HAT (4), 
PVT {l)c 
Moderate AR (4), Cholangitis (1), CMV (1) Candida (1), Focal 
BON (1) 
Partial IH·HAT (3), HAT (1)c, HAT + PVT (1)c Cholangitis {l), 
CMV (3), E-B (1), Focal BON (2), Moderate CR (1) 
Moderate AR (8), CMV (2) 
Severe AR (2), PartialIH-HAT (1), Partial IH-PVT (1) 
Partial IH·HAT (1), Moderate CR (2) 
See text 
IH = intrahepatic; CMV = cytomegalovirus infection; E-B = Epstein·Barr virus infection; BDN = bile duct necrosis. 
aMean + S.E.M. 
bp < 0.001 VS. all groups. 
cConsidered as final secondary events, not the main cause of graft failure. 
d p < 0.01 vs. groups 2, 3 and 4. 
'See text for specific causes. 
obtained retrospectively after the failed allograft had been 
thoroughly examined pathologically were considered to be 
correct. Those not matching and poorly defined or nonspecific 
indications for re·OLTx were considered to be wrong. 
The amount of RBCs, number of platelet packs, units of 
fresh frozen plasma and units of cryoprecipitate administered 
to each patient during the first 0 L Tx procedure were obtained 
from the operative, anesthesia and blood bank records. 
StatiBtical AnaIYBu. All numerical data were expressed as 
mean values ± S.E.M. Their conformity to a normal distri· 
bution was assessed by the Kolmogorov·Smirnov method. 
Multiple comparisons were made using ANOVA followed by 
the Scheffe test for group-to-group comparisons (for nonnal 
distributions) or by the nonparametric Kruskal·Wallis test 
followed by the Mann-Whitney U test for variables that were 
not normally distributed. Student's t test or the Mann-
Whitney U test were used for isolated comparisons between 
two groups. The x2 test (with or without Yates' correction) was 
used for comparisons of qualitative variables. Actuarial sur-
vival of the patients was calculated by the life tables method. 
RESULTS 
Causes and Timing of Graft Failure. The 177 pa-
tients included in the analysis represented 19.6% of the 
total population receiving a first OLTx at the University 
of Pittsburgh during the period encompassed by the 
study. The causes of graft failure, the respective mean 
graft survival time and the pathological findings present 
in the removed allografts are summarized in Table 2. 
PNF accounted for 30% (n = 53) of the failed grafts, 
In two cases, preexistent abnormalities in the donor liver 
(severe fatty change) may have been responsible for the 
failure of the graft to function, whereas in the remaining 
51 cases a harvest-related injury was considered to be 
the principal factor responsible for the graft failure. In 
four cases, hyperacute humoral-mediated rejection was 
suspected as being present but was not proven. 
IJ was the cause of graft failure in 9.6% (n = 17) of 
the cases. A severe parenchymal necrosis, predomi-
nantly centrilobular, was found in all of these grafts. 
AR was the cause of graft failure in 10.7% (n = 19) of 
the cases. Two of these were thought to represent 
episodes of hyperacute, humoral-mediated rejection, 
whereas 17 were thought to be a result of cell-mediated 
rejection. In the two cases with hyperacute rejection, a 
linear deposition of immunoglobulin and complement 
along the hepatic vessels could be demonstrated immu-
nohistochemically. 
A VC accounted for 26.6% (n = 47) of the failed grafts. 
Of these, 31 patients had HA thrombosis (HAT), 6 
patients had PV thrombosis (PVT), 4 patients had HAT 
plus PVT, 1 patient had a suprahepatic inferior vena 
cava thrombosis and the remaining 5 patients had a 
nonthrombotic complication of the HA (stenosis in 2 
cases and 1 case each of vascular-biliary fistula, mural 
degeneration and dissection of the donor HA). Among 
the 31 cases of HAT, 2 were a consequence of an attempt 
to repair an arterioportal fistula and an HA aneurysm. 
In one case, the HA was occluded as a result of focal 
fibrointimal hyperplasia. The findings present in these 
failed grafts included bile duct necrosis with a biliary 
leak in 12 patients, massive or submassive parenchymal 
necrosis in 32 patients and liver abscesses or microab-
scesses in 14 patients. 
Twenty grafts (11.3%) failed because of CR. The 
earliest such case was one of acute vanishing bile duct 
syndrome. 
REC in the allograft was established in only eight 
cases. Seven were a result of recurrent type B virus 
infection and produced FHF of the liver graft (one 
patient), severe acute hepatitis (three patients), CAlI 
(one patient) and cirrhosis (two patients). The re-
maining case was that of a recurrent HCC. Another four 
patients were included in this category although the 
diagnosis ofREC could not be defined absolutely. Two of 
these four patients were transplanted for end-stage 
autoimmune hepatitis and the allograft developed a 
picture of CAlI of the autoimmune type similar to that 
of the native liver. In addition, both of these livers also 
e 
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FIG. 2. Timing of graft failure according to primary liver disease 
among the 177 patients studied. MISe = patients with FHF, NLD and 
miscellaneous conditions (see text for specific disease included in each 
category). 
showed findings consistent with moderate AR. One 
patient with FHF attributed to NANB virus infection 
had acute hepatitis in the allograft develop in which all 
other causes of graft failure could be eliminated_ A 
second patient with CAH plus cirrhosis thought to be 
caused by NANB hepatitis had a similar histopatho-
logical picture in the allograft develop. 
Finally, 5% (n = 9) (MISC) of the cases did not fill any 
of the preceding identifiable categories. They included 
the following: nonrecurrent HBV (two' cases), one of 
which was associated with severe CR; herpes hepatitis 
(one case); acute hepatitis of unidentified origin plus 
severe CR (one case); suppurative cholangitis (one case); 
severe acute cholangitis with associated ischemic 
damage (one case); bile duct necrosis with bile leak and 
associated cytomegalovirus hepatitis (one case); and 
two cases in which the cause of graft failure could not be 
established. 
Timing of Graft Failure. Mean graft survival for all 
patients was 130.6 ± 22.9 days (range = 0 to 2,073)' 
The number of failed grafts decreased progressively with 
increasing time after OLTx, with 67.8% of all graft 
failures occurring in the first postoperative month and 
only 6.2% occurring 2 yr or more after OLTx (Fig. 1). 
The mean graft survival of organs that failed because of 
PNF, IJ, AR and VC was significantly less (p < 0.05 or 
less) than that for grafts that failed because of CR or 
REC. In addition, among these four causes of early graft 
failure, PNF occurred significantly earlier than did any 
of the other three (p < 0.001) (Table 2). 
A highly significant association (p < 0.001) was found 
between the cause and timing of graft failure when the 
population was distributed into the six time periods used 
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FIG. 3. (A) Actuarial survival after a second liver transplant for the 
177 patients included in this study. (H) Influence of the cause of the 
initial graft failure on the survival of the patients after the second liver 
graft. For IJ, n = 17; for REC, n = 12. MISe = patients with failed 
grafts because of PNF, AR, VC, CR and nonclassified causes (see text 
for specific conditions included in each group). 
to classify the timing of graft failure (Table 3), Despite 
some minor overlap, the data in this table clearly 
demonstrate that early causes of graft failure are PNF. 
IJ, AR and VC, whereas late causes are CR and REC. 
Characteristics of the Recipients Relative to the 
Cause and Timing of Graft Failure. The causes of graft 
failure were significantly different between patients who 
had transplants because of PLD and those who had 
transplants because of ChLD (p < 0.05) (Table 4). The 
principal differences between these two groups was the 
higher frequency of PNF and REC in the PLD group and 
the higher number ofVC and CR in the ChLD group. In 
addition. it should be noted that 50% of patients with 
FHF had graft failure develop because ofVC (HAT in all 
cases l. Mean graft survival did not differ significantly 
among the various groups based on primary liver disease 
(ChLD = 89.1 ± 25.5 days; PLD = 166.2 ± 41.2 days; 
NLD = 96.3 ± 51.4 days; and FHF = 195.7 ± 92.1 
days). The only exception was the very short graft 
survival found for patients within the MISC group 
(4.5 ± 1.1 days [p < 0.01 vs. ChLD, PLD and FHF]). 
Figure 2 graphically illustrates the parallel timing of 
graft failure in the three major primary liver disease 
groups. 
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TABLE 3. Time distribution of the caUllefl of graft fallure in 177 casetJ studied 
Timing of graft failure (%) 
Caue of ailograft failure Number of c.- 0-14 da)'ll 15-30 da)'ll 2-8 mo 7-12 mo 13-24 mo More than 24 mo Total (%) 
PNF 53 100 100 
IJ 17 58.8 29.4 11.8 100 
AR 19 42.1 15.8 42.1 100 
VC 47 53.2 29.8 8.5 2.1 4.3 2.1 100 
CR 20 30 30 10 30 100 
REC 12 33.3 16.7 25 25 100 
MISC 9 ILl ILl 33.3 ILl 22.2 11.1 100 
x2 value for the distribution '" 174.28 (p < 0.001). 
TABLE 4. Relationship between cause of graft failure and primary liver disease in 177 casetJ studied 
Primary liver Namber of Vaaealar 
diM""" c_ PNF (%) IJ (%) AR (Ok) thromboeia (Ok) CR (%) REC (%) MUc (%) Total (%) 
1. ChLDb 54 18.5 ILl ILl 
2. Chronic PLD 85 35.3 8.2 13.0 
3. NLD 16 31.2 18.7 6.3 
4. FHF 14 14.3 0 7.1 
5. MISC 8 75 12.5 0 
aSee text for specific diseases mcluded in each category. 
b1 VS. 2: x' value = 15.93 (p < 0.05>. 
The patient's gender did not significantly influence 
mean graft survival (men = 139.3 ± 35.5 days and 
women = 120.5 ± 27.9), nor did gender affect the cause 
of graft failure (PNF = 30.8% vs. 28.9%, IJ = 8.5% vs. 
10.8%, AR = 12.7% vs. 8.4%, VC = 25.5% vs. 27.8%, 
CR = 8.5% vs. 14_4% and MISC = 4.2% vs. 7.2%), 
although REC was more frequent in men (10.6% vs. 
2.4%, 0.1 > p > 0.05). This latter difference was the 
result of the fact that all cases of recurrent type B virus 
infection occurred in men. 
The mean age of the patients in the ischemic injury 
group (49.8 ± 2.2 yr) was significantly greater than it 
was for patients whose grafts failed because of PNF 
(4lt.3 ± 1.8 yr, p < 0.01), AR (35.5 ± 2.7 yr, p < 0.01) 
andi CR (36.0 ± 2.7 yr, p < 0.01). Of interest, the 
subgroup of patients with PVT was the oldest 
(53.8 ± 11.3 yr) (p < 0.01) vs. all causes of graft 
failure). In addition to these differences between groups, 
patients with an immunological cause of graft failure 
were significantly (p < 0.01) younger (35.8 ± 1.9 yr) 
than those with graft ischemic injury (44.0 ± 2.0 yr) as 
a result of other causes (43.4 ± 1.5 yr). Patients whose 
grafts survived for more than 1 yr (31.4 ± 3.1 yr, 
n = 20) were significantly younger than those whose 
grafts did not survive a full year. The mean age of those 
whose grafts failed in the first postoperative month was 
43.3 ± 1.2 yr tn = 120, P < 0.01), whereas those whose 
graft failed in the second through twelfth postoperative 
months was 40.4 ± 2.1 yr (n = 37, p < 0.01). 
Intraoperative Conaumption of Blood and Blood 
Product.. The intraoperative requirement of RBCs 
(25.1 ± 2.8 vs. 16_9 ± 1.7 units, p < 0.05), platelets 
(19.6 ± 1.8 vs. 10.3 ± 1.3 units, p < 0.001), fresh 
frozen plasma (18_3 ± 2.2 vs. 10.2 ± 1.4 units, 
p < 0.01) and cryoprecipitate (9.5 ± 1.4 vs. 5.2 ± 1.2 
37.0 16.7 
20.0 9.4 
12.5 12.5 
50 7.1 
12.5 0 
0 
11.8 
6.3 
7.1 
0 
5.6 
2.3 
12.5 
14.3 
0 
100 
100 
100 
100 
100 
units, p < 0.05) was significantly greater in patients 
with PLD (n = 85) than for all other disease groups 
(n = 84), excluding those in the MISC category (n = 8). 
This latter group required the greatest amount of blood 
products. 
Relevant to the issue of graft failure, the greatest 
requirement for blood products was by patients in the 
PNF and ischemic injury groups (Table 5). Thus a 
significantly greater requirement for blood and blood 
products was seen in patients with graft failure oc-
curring in the first postoperative month (Table 6). 
Preoperative Diagnosis of the Cause of Graft Failure. 
A preoperative diagnosis for graft failure was not 
specifically identified in the record of seven patients. In 
addition, if the patients in the ischemic injury group are 
excluded from the analysis because this diagnosis is not 
evident until the liver is removed, a total of 153 cases 
were available for analysis. The overall accuracy of the 
preoperative diagnosis for the cause of graft failure was 
77.7%. The greatest diagnostic accuracy rate was found 
for CR (100%). Second was REC (91.6%). The poorest 
rate was obtained for cases with VC (63.8%), AR (66.6%) 
and MISC (66.6%). The diagnosis of PNF as a cause of 
graft failure occupied an intermediate value (84.0%). 
Thus the preoperative diagnostic accuracy rate for 
causes of graft loss was significantly better for late 
failures (92.4% accurate) than it was for early failing 
grafts (70.0% accurate) (p < 0.01). 
Patient Survival A(fer the Second OLTx-6-Mo Sur-
vival. Overall 6-mo survival after a second OLTx was 
46.3%. With regard to the cause of first-graft failure, the 
greatest second-graft survival rate was achieved by 
patients in the CR group (65%). The group with the 
poorest second-graft survival rate consisted of those 
patients with ischemic injury (23%, p < 0.05) as the 
3 
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TABLE 5. Intraoperative requirement for blood and blood products at the time of first OLTx and subsequent cause of graft 
failure in 177 patients studied 
CaUlle of graft Plateleta Fresh frozen Cryoprecipitate 
failure RHe. (units) (unita) pluma (units) (units) 
1. PNF 33.1 ± 4.2" 20.5 ± 2.5b 21.8 ± 3.5e 12.6 ± 2.0" 
2. IJ 33.8 ± 9.5d 14.2 ± 4.7d 19.9 ± 6.2 6.8 ± 4.1 
3. AR 16.3 ± 3.5 13.1 ± 3.2 12.8 ± 3.0 6.7 ± 2.2 
4. VC 18.0 ± 2.6 13.5 ± 1.8 9.8 ± 1.4 4.8 ± 1.1 
5. CR 7.8 ± 1.0 8.1 ± 2.S 6.4 ± 1.0 1.7 ± 0.9 
6. REC 18.4 ± 2.4 18.1±3.7 15.S ± 3.9 6.8 ± 2.4 
7. MISC 20.7 ± 2.2 13.0 ± 3.8 15.3 ± 3.4 9.S ± 4.8 
Results are mean ± S.E.M. 
"p < 0.01 VB. 3, 4 and 5. 
bp < 0.05 vs. 3 and 4, and p < 0.01 VB. 5. 
c p < 0.01 vs. 4 and 5. 
d p < 0.01 VS. 5. 
cause for the failure of their first graft. Patients in 
the remaining groups, classified on the basis of first-
graft failure, showed intermediate survival rates 
(PNF = 49%, AR = 53%, VC = 49%, REC = 33%, and 
MISC = 33%). Second-graft 6-mo survival was signifi-
cantly greater for recipients younger than 40 yr at the 
time of the initial OLTx than it was for those who were 
older than 40 yr at the time of first grafting (56.4% vs. 
39.4%, p < 0.05). Recipient gender (men = 44.7% and 
women = 50.6%) did not affect second-graft survival 
rates. 
No significant difference for second-graft 6-mo sur-
vival was evident for patients in the different disease 
groups used to classify the original liver disease 
(ChLD = 44%, PLD = 48%, FHF = 50%, NLD = 50% 
and MISC = 37%). Among patients with PLD, those 
with HBV = induced cirrhosis showed a significantly 
poorer 6-mo survival (16.6%, n = 18) than did all 
remaining groups (57.8%, n = 67, P < 0.01). 
Patients who survived after the second liver graft for 
6 mo or more were younger and had a significantly 
smaller first-OLTx requirement for blood and blood 
products (Table 7). 
Actuarial Survival for Second Liver Grafts. The 
actuarial survival of the patients included in this study 
from the time of their second OL Tx is illustrated in 
Figure 3A. Most of the deaths (45%) after the second 
OLTx occurred in the first 2 mo after the second 
transplant procedure. The death rate was minimal after 
an initial 12 mo. The influence of the cause of first-graft 
failure on second-graft patient survival is shown in 
Figure 3B. The poor prognosis for patients with first-
graft failure caused by ischemic injury and disease 
recurrence is clearly demonstrated. All of the patients in 
the remaining categories for cause of first-graft failure 
can be viewed as a single group because their respective 
survivals after second grafting were similar. 
DISCUSSION 
This study has identified the principal causes and the 
timing of graft failure after initial OLTx in a population 
of patients who received a second OL Tx. In most studies 
performed before this, the cause of graft failure has been 
TABLE 6. Intraoperative requirement for blood and blood 
products at time of first OLTx and timing of subsequent 
graft failure in 177 patients studied 
Timing of graft failure 
Less than More than 
Blood or blood product 30 days 30 days p value 
RBCs (units) 27.S ± 2.6 12.8 ± 1.S <0.001 
Platelets (units) lS.9 ± 1.5 11.4 ± 1.5 <0.05 
Fresh frozen plasma (units) 17.4 ± 2.0 9.8 ± 1.3 <0.01 
Cryprecipitate (units) 8.9 ± 1.2 4.1 ± 0.9 <0.01 
Values are mean ± S.E.M. 
classified into three or fewer groups, such as PNF, 
rejection and technical complications (5-7). This study 
extended such data and examined graft failure across six 
distinct categories. In addition, a characteristic timing 
for each type of graft failure was demonstrated. Thus 
despite some overlap in the period from 2 to 6 mo after 
initial OLTx, these results demonstrate that the main 
causes of early graft failure are PNF, ischemic injury, AR 
and VC, whereas those for late graft failure are CR and 
REC. 
The first postoperative month constitutes the period 
of greatest risk for graft failure after OLTx. A total of 
67% of the grafts fail in this first month. During this 
same period, PNF is the single most frequent cause of 
graft failure and accounts for 42% of the early cases of 
graft loss and for 30% of the total graft losses inde-
pendent of time. 
The specific mechanisms responsible for PNF remain 
to be determined but clearly include prolonged warm 
and cold ischemia times, preservation and reperfusion 
injuries and other less well-identified injuries. In only 
two cases were specific abnormalities of the donor 
identified as possible causes for subsequent graft failure. 
In the remaining cases, a putative harvest injury 
(prolonged warm or cold ischemia or reperfusion injury) 
was the most frequent probable underlying factor. 
However, it is also quite likely that other factors may 
have contributed to the graft injury that ultimately 
resulted in the phenomenon collectively identified as 
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TABLE 7. ID1luence of factors related to first OLTx on 6-mo patient survival after second OLTx 
First-graft 
Intraoperative needs during first OLb (unit. I 
Patient survival after 
secondOLb Number Age (yr) survival (days) RBC Platelets FFP Cryoprecipitate 
Six-month survivors 
Six· month nonsurvivors 
Statistical significance 
83 
94 
38.8 ± 1.5 155.9 ± 33.4 19.2 ± 2.4 11.7 ± 1.4 10.4 ± 1.7 6.5 ± 1.3 
43.5 ± 1.3 108.3 ± 31.3 26.2 ± 2.7 18.1 ± 1.7 18.7 ± 2.1 8.0 :!: 1.2 
Results are mean ± S.E.M. 
FFP = fresh frozen plasma. 
P < 0.05 NS 
PNF. Hemodynamic instability is a frequent problem in 
patients with PNF, as judged by their requirements for 
blood and blood products during the OLTx procedure. 
Whether this initiates a primary malfunction of the 
donor organ, occurs as a result of intraoperative com-
plications derived from technical factors, is a particular 
characteristic of the recipient at risk for PNF or is even 
a combination of these factors remains to be determined. 
The greater frequency ofPNF in patients with PLD than 
in those with ChLD suggests that recipient factors may 
contribute. at least in part, to the development of PNF. 
Until accurate methods are available to determine the 
degree of graft function immediately before and after 
implantation, the role of recipient factors in the patho-
genesis of PNF will remain uncertain. Although hyper-
acute humoral-mediated rejection is considered to be a 
relatively infrequent event in OLTx (14), the possibility 
cannot be excluded that many, if not most, of the cases 
of PNF are mediated. at least in part, by immunological 
events. In this series, only two cases of probable 
hyperacute rejection could be identified. Because the 
characteristic vascular deposition of complement and 
immunoglobulins is transient in cases of hyperacute 
rejection (14), cases can either be missed altogether or 
masked, and as a result they are entered inappropriately 
into the generic category of PNF. It is also important to 
note that either hyperacute rejection or reperfusion 
injury can initiate a severe coagulopathy that leads to 
bleeding, hypoperfusion and a requirement for more 
blood and blood products, each of which can either 
initiate or contribute further to the other existing factor 
or factors that lead to PNF. The identification of these 
additional factors possibly responsible for PNF and 
whether they are of donor, harvest or recipient origin 
should allow either for their amelioration or elimination 
and, as a result, lead to a substantial improvement in 
OLTx results. 
This study revealed a heretofore unrecognized cat-
egory of graft failure found in the early post-OLTx 
period. Specifically, 17 patients were found to have graft 
necrosis in the absence of any identifiable vascular 
complication (lJ). Among these cases, a partial or total 
recovery of initial graft dysfunction was evident followed 
later by graft loss sometime after the first postoperative 
week. Thus this group of graft failures is clearly 
different from those in which PNF is evident immedi-
ately. The intraoperative requirement for blood and 
blood products in this latter group of patients was equal 
to or greater than that seen in those with PNF. 
P < 0.05 p < 0.01 P < 0.01 NS 
Moreover, the mean age of the patients in this new 
category was greater than in any other category and 
suggests that poor recipient condition may have been an 
underlying factor for the graft failure in this group. It is 
important to emphasize that no case of ischemic injury 
wsa found in patients younger than 30 yr and then only 
in two patients younger than 40 yr. Although ischemic 
injury represented only 9.6% of the total cases of graft 
failure, its importance derives from the very poor 
outcome of this subgroup of patients after the second 
OLTx. It is likely that the underlying systemic factors 
leading to an initial graft failure in this group also 
contribute substantially to the poor outcome of these 
patients after their second OLTx. 
Rejection accounted for 39 graft losses, half of which 
were AR and half of which were CR. Rejection, therefore, 
accounts for 22% of the total graft failures after OLTx. 
Thus despite the fact that AR occurs in about 70% to 
80% of all OLTx recipients (1-3), uncontrollable re-
jection that leads to graft failure is quite unusual. 
Nonetheless, these same data also highlight the need for 
better immunosuppressive reagents and regimens to 
control severe episodes of graft rejection. In this context, 
the recent results obtained in a small series of patients 
with the new immunosuppressant, FK 506, are ex-
tremely encouraging (15). Because this drug appears to 
be useful in the management of both AR and CR, the 
need for repeat transplants for rejection ought to be 
reduced in the future as this drug becomes more widely 
available. 
ves were the second leading cause of graft failure 
after OL Tx. This observation is in agreement with the 
relatively high frequency of vascular problems demon-
strated in previous studies ofOLTx recipients (5-7,16). 
These complications were predominantly early events, 
with all but five cases occurring within the first 3 mo 
after the operation. Among the various types ofVC, HAT 
was the most frequent. Initially considered to be a 
technical event, recent reports suggest that other factors 
may also predispose the recipient to experience this 
particular complication. High hematocrit values, low HA 
blood flow rates, infection, rejection and other factors, 
(13, 17, 18) are believed to represent nontechnical risk 
factors for the development of HAT, although some of 
these factors might not be relevant to adult patients 
(19). These issues have not been addressed in this study. 
Moderate or severe AR was documented in 8 of 26 
grafts removed because of HAT within the first 3 rno 
after the operation, suggesting that the coupling rate of 
f 
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such conditions might be greater than that expected on 
a random basis. Additional studies to search for such an 
association are thus warranted. PVT was an infrequent 
complication in this series (5-7, 16). 
These results reemphasize the previously reported 
high rate of recurrence of HBV infection in the liver 
allograft (20). Because no effective method is yet 
available to prevent this complication, it remains a major 
problem for patients who have transplants for this 
indication U, 3). Despite an almost universal disease-
recurrence rate in patients who have transplants for this 
indication, the mean first-graft survival in these par-
ticular patients was 550 days, a time period sufficiently 
long to make HBV infection a relative rather than an 
absolute contraindication for OL Tx. The low recurrence 
rate of neoplasia in this series should be considered 
cautiously because most patients with neoplastic disease 
whose grafts failed had them do so in the early 
postoperative period as a result of a variety of causes 
other than recurrent disease. Recurrence of the original 
hepatic malignancy within a graft requires initial sur-
vival and is a frequent cause oflate death or graft failure 
(21. 22l. Whether disease recurrence occurs in cases of 
NANB or autoimmune hepatitis remains to be deter-
mined. In contrast to recent reports (22) claiming re-
currence of PBC in liver allografts, such a condition 
could not be identified in this large series consisting of 
33 patients with PBC as the indication for their 
transplant. 
Biliary tract complications were one of the more 
prominent sources of morbidity and mortality in the 
initial years of OLTx (9); technical improvements have 
led to a reduction of such problems in the last several 
years (9. 23). Severe biliary tract complications found in 
removed grafts were thought almost universally to be 
secondary to HAT because the blood supply for the 
extrahepatic bile ducts in these cases is dependent solely 
on HA flow. Thus it is essential to specifically evaluate 
the HA in all patients with suspected or recognized 
biliary tract complications. 
With regard to the preoperative diagnosis of the cause 
for first-graft failure, the marked difference observed in 
the diagnostic accuracy rate for early and late graft 
failures highlights the complexity of the early postoper-
ative period. The many different causes capable of 
leading to graft failure during this period and the 
multitude of complications that can occur in the imme-
diate postoperative period (1-4, 11) probably determine 
the difficulty in establishing an accurate preoperative 
diagnosis in such cases. In contrast, the almost 100% 
diagnostic accuracy rate observed after the first 
post-OLTx month indicates that in most patients iden-
tifying a specific cause for graft failure beyond the first 
postoperative month is not a clinical problem. 
The overall patient survival rates of 55% at 2 mo and 
46% at 6 mo after a second OLTx and the actuarial 
survival of 43% at 1 yr and 35% at 4 yr clearly document 
that the initial 6-mo postoperative period and specifi-
cally the first 2 mo after retransplantation constitute the 
period of highest risk for mortality for patients under-
going a second OLTx. However, it should be emphasized 
that the late mortality is very small, rendering the 
prognosis for patients surviving beyond this initial 
critical period quite good. Second-transplant patient 
survival rates herein reported are higher than those 
found in a study that included patients from four centers 
(8), but they are comparable with those obtained from 
this institution some years ago (5) and other centers (6), 
despite the small number of cases included in both of 
these earlier series (5, 6). Although quantitatively 
different, the high mortality seen in the early postoper-
ative period after second OLTx closely mimics the 
evolution of patients subjected to a single OLTx pro-
cedure (1, 3). The poorer prognosis for retransplanted 
patients may be related to the setting in which retrans-
plantation must be performed (5), Excluding the above 
mentioned cases of patients who had retransplants 
because of ischemic injury and disease recurrence and 
whose prognosis was poor, the precise reason for 
retransplantation seems to have little or no effect on 
subsequent patient survival. Thus retransplantation 
because of PNF might not be associated with a poor 
prognosis as has been reported previously (5). In 
addition, other factors likely to influence early patient 
survival after liver retransplantation have been iden-
tified as a result of this study. Advanced age and an 
excessive requirement for blood and blood products at 
the time of the first OLTx appears to represent a risk 
factor for early death after a second OLTx. Whether a 
significant association exists between these factors and 
a specific cause of death after retransplantation has not 
been addressed as part of this study. 
In summary, this study establishes a pattern of causes 
and timing of first allograft failure based on the results 
observed in a large population of patients undergoing 
liver retransplantation. In addition, it confirms the 
effectiveness of the use of liver retransplantation as a 
life-saving maneuver for patients whose first allograft 
fails. 
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